Neovici Holding AB (publ)
Research Neovici Holding AB (publ) (IDLDX) on Bullrun: market cap SEK 95.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIDLDX
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencySEK
- Market capSEK 95.60M
- Financial periodQ4 2025
- RevenueSEK 16.30M
- Net income-SEK 1.47M
- Free cash flowSEK 105.00K
- Gross margin59.1%
Valuation Snapshot
latest market cap is SEK 95.60M.
About Neovici Holding AB (publ)
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies.
Frequently asked questions
What is Neovici Holding AB (publ)'s market cap?
Neovici Holding AB (publ)'s market capitalization is SEK 95.60M.
What does Neovici Holding AB (publ) do?
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells;